Pharma Pulse 4/5/24: Is 2024 the Year for Psychedelic Medicine? Barriers Impacting Enrollment in Lung Cancer Trials & more


The latest news for pharma industry insiders.

Barriers Impacting Patient Enrollment in Lung Cancer Trials

Systematic review of available literature aimed to identify the most prominent barriers affecting enrollment in oncology drug trials.

Is 2024 the Year for Psychedelic Medicine?

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

Patient With Transplanted Pig Kidney Leaves Hospital for Home

Richard Slayman, 62, is the first patient to receive a kidney from a genetically modified pig. Two weeks after the procedure, he was well enough to be discharged, doctors said.

GoodRx Adds Publix to GoodRx Gold Network

Monthly healthcare membership now provides consumers with savings of up to 90% at more than 1,200 Publix locations

Model N on LinkedIn:

"The Inflation Reduction Act (IRA) is already shaking up the industry and may create unintended consequences, but we won't know the full impact for a few years," said Michael Grosberg. "As manufacturers navigate the impending changes, they must optimize their revenue management processes."

Learn more about how the #pharma industry may evolve, the state of the pharmacy benefit manager (PBM) model, price transparency models, and more in this Pharmaceutical Commerce Magazine article.

#LifeSciences #RevenueOptimization #RevenueManagement #ThoughtLeadership

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs

© 2024 MJH Life Sciences

All rights reserved.